CIITA anticorps (N-Term)

N° du produit ABIN285417

Détail du produit anti-CIITA anticorps

Antigène: CIITA (Class II, Major Histocompatibility Complex, Transactivator (CIITA))

Épitope: N-Term

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp CIITA est non-conjugé

Application: Western Blotting (WB), ELISA

Purification: Ion exchange chromatography

Immunogène: Ciita antibody was raised in rabbit using CIITA peptide corresponding to a region near the N-terminus of the human protein conjugated to KLH as the immunogen.

Information d'application

Indications d'application: ELISA: 1:5,000-1:25,000, WB: 1:500-1:3,000
Optimal conditions should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Concentration: Lot specific

Buffer: Lyophilized from 0.02 M K2 O4, pH 7.2, with 0.12 NaCl and 0.01 % NaN3.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium Azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use.

Stock: -20 °C

Stockage commentaire: Store at -20 °C. Aliquot and freeze at -20 °C or below for long term storage.

Détails sur CIITA

Antigène: CIITA (Class II, Major Histocompatibility Complex, Transactivator (CIITA))

Autre désignation: Ciita (CIITA Produits)

Synonymes: anticorps CIITA, anticorps C2ta, anticorps EG669998, anticorps Gm9475, anticorps C2TA, anticorps CIITAIV, anticorps MHC2TA, anticorps NLRA, anticorps Mhc2ta, anticorps class II, major histocompatibility complex, transactivator, anticorps class II major histocompatibility complex transactivator, anticorps MHC class II transactivator, anticorps class II transactivator, anticorps CIITA, anticorps LOC710761, anticorps ciita, anticorps LOC100443575, anticorps Ciita, anticorps LOC100736732

Sujet: CIITA is a human gene which encodes a protein called the class II, major histocompatibility complex, transactivator. Mutations in this gene are responsible for the bare lymphocyte syndrome in which the immune system is severely compromised and cannot effectively fight infection.

Pathways: Cancer Immune Checkpoints